Pharmather (CSE: PHRM) is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Pharmather was founded with a particular focus on repurposing psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system.
Their team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets.
Pharmather's goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and advance our clinical product pipeline with ketamine and psilocybin in Parkinson’s disease, depression, traumatic brain injury and stroke. For more information, visit www.pharmather.com.
PharmaTher is advancing research and development through the discovery psychedelics and combinations with FDA approved drugs with panaceAI™, the Company’s drug repurposing platform.
Pharmather has a research partnership with Dr. Phedias Diamandis' lab (Diamandis Lab II) at the University Health Network, based in Toronto, Ontario, for the development of panaceAI™. The current focus of panaceAI™ is finding effective uses of drugs for rare disorders, infectious diseases and effectives uses of psychedelic-derived medicines. The research team at UHN will build out panaceAI™ to serve as a software suite that leverages machine learning to curate and rank the most relevant drug interactions, binding affinities, drug-disease similarities and structural comparison tools to make data-driven drug predictions. panaceAI™ aims to serve as the Company’s product pipeline engine and upon further validation, panaceAI™ will be commercialized to acquire partnership opportunities with biotechnology and pharmaceutical companies globally.
PharmaTher's product pipeline targeting rare disorders (Neurological and pain) and infectious diseases, which target attractive regulatory incentives for expedited approvals, such as the FDA 505(b)(2) regulatory pathway and orphan drug, fast track and breakthrough designations.